title: [Enterosan--perspective medications for patients with postinfection irritable bowel syndrome].
abstract: The pathogenesis of PIBS matter transferred intestinal infections that lead to persistent intestinal dysbiosis. The aim of this study was to investigate the effectiveness of enterosana at PIBS.
  
  
  METHODS
  A total of 37 patients with PIBS diarrhea included in the study group and 30 patients consisted the control group. Diagnosis PIBS installed in accordance with the criteria of the Rome Consensus II. To assess the intestinal microflora were sown feces and made hydrogen breath test.
  
  
  RESULTS
  In the study group patients by the end of the 3-week course enterosan therapy was appeared stable clinical PIBS remission. In the reseeding of feces decreased levels of conditionally pathogenic microflora and increased to normal number of bifidobacteria and lactobacilli. Were normalized rates of hydrogen in exhaled air according to breath test, which reflects bacterial overgrowth in the lumen of the small intestine.
  
  
  CONCLUSIONS
  Enterosan has good therapeutic effect in treating patients with PIBS, helps to restore normal intestinal microflora and improve intestinal digestion.
authors.forename: A I
authors.initials: AI
authors.lastname: Parfenov
authors.forename: I N
authors.initials: IN
authors.lastname: Ruchkina
mesh_terms: D000328:Adult; D001944:Breath Tests; D003967:Diarrhea / Q000150:complications* / Q000382:microbiology; D005243:Feces / Q000382:microbiology; D005260:Female; D006025:Glycosaminoglycans / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects / Q000382:microbiology; D007421:Intestine, Small / Q000187:drug effects / Q000382:microbiology*; D043183:Irritable Bowel Syndrome / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D008297:Male; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D006025:Glycosaminoglycans; C534259:enterosan